Search Bar & Filters
Found 210 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying relapsed or refractory multiple myeloma in adults who have already received treatment with lenalidomide and a proteasome inhibitor but whose disease has progressed. The study aims to evaluate the effects of adding SG301 injection to the standard treatment of pomalidomide and dexamethasone. This is a randomized, placebo-controlled, double-blind, multicenter phase III clinical trial. The study has two stages. Stage 1 is to find the right dose of SG301 combined with pomalidomide and dexamethasone. Stage 2 randomly assigns participants to receive either SG301 injection plus pomalidomide and dexamethasone or a placebo plus the same drugs. SG301 and its placebo are given by intravenous infusion weekly for 8 weeks, then every 2 weeks. Pomalidomide capsules are taken orally once daily on days 1 to 21 of each 28-day cycle. Dexamethasone is taken orally or by infusion on days 1, 8, 15, and 22, with dose adjusted for low body weight. Participants continue treatment until their disease progresses, unacceptable side effects occur, or other stopping criteria are met. Researchers will monitor side effects, drug levels in the body, immune response, and treatment effects including progression-free survival and overall survival for up to about 4 years. The study includes regular assessments every 4 weeks initially, then every 8 weeks, with safety followed for about 30 days after treatment ends.
Actively Recruiting
Researchers are evaluating a study medicine called MK-1045 in adults with systemic lupus erythematosus SLE or rheumatoid arthritis RA. This phase 1 clinical trial aims to learn about the safety and how well people tolerate MK-1045 when given at different dose levels. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment outcomes for these autoimmune conditions. Participants will receive MK-1045 through intravenous IV infusion in varying ways depending on their study group. Some will get a single IV dose at different dose levels, while others will receive three step-up doses over a 3-week interval, progressing from a prime dose to a target dose. The study includes dose escalation panels and an optional dose expansion phase for further evaluation. During the study, participants will be monitored for adverse events up to 52 weeks. Researchers will assess the number of participants experiencing side effects or discontinuing the drug due to side effects. Blood tests will measure MK-1045 levels and the effect on peripheral B cell counts at specific times. This detailed monitoring helps understand the drugs safety, pharmacokinetics, and pharmacodynamics throughout the trial duration.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.
Actively Recruiting
Researchers are evaluating the safety and tolerability of AWT020 alone and in combination with other antitumor therapies in patients with advanced cancers such as non-small cell lung cancer, colorectal cancer, renal cell carcinoma, melanoma, and other solid tumors. This phase I clinical study aims to assess these treatments in patients who have failed or are intolerant to standard therapies or have no standard treatment options. The study also explores pharmacokinetics and efficacy outcomes. Participants receive AWT020 either alone or combined with drugs including Taxol, Cisplatin or Carboplatin, Pemetrexed, Oxaliplatin, Capecitabine, Bevacizumab, or Renvastinib. Dosing schedules vary by drug, for example, Taxol is given every three weeks at 135-175 mgm, while AWT020 is administered intravenously every two or three weeks. The study includes single-agent dose escalation and expansion phases, as well as combination treatment phases, tailored to specific cancer types and prior treatment histories. During the study, participants undergo regular monitoring for dose-limiting toxicities, adverse events, and serious adverse events for up to 12 months. Pharmacokinetics and immunogenicity are evaluated for up to 24 months, while response rates, duration of response, disease control, progression-free survival, and overall survival are assessed up to approximately 32 months. Patients have scheduled visits for treatment administration and safety assessments, with adherence to contraception requirements for fertile participants. The total study duration extends until April 2028.
Actively Recruiting
Researchers are evaluating TQB2102 for injection, a new antibody-coupled drug that targets two different parts of the HER2 protein on tumor cells. This study focuses on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. The trial aims to assess the effectiveness and safety of TQB2102 combined with benmelstobart or penpulimab, with or without chemotherapy, in this patient group. This is a Phase II randomized study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive TQB2102 for injection and either benmelstobart or penpulimab, both given intravenously every three weeks. Chemotherapy is taken orally from Day 1 to Day 15 in each 21-day treatment cycle. There are three study groups, each involving different combinations and doses of TQB2102, benmelstobart, penpulimab, and chemotherapy. Treatment continues through multiple cycles as determined by the study protocol. During the study, participants undergo regular assessments including scans and tests to measure tumor response and disease progression. Researchers monitor outcomes like the objective response rate, progression-free survival, duration of response, overall survival, and any adverse events. The study includes follow-up periods to track safety and effectiveness, with an average observation of up to three years. Participants are closely monitored throughout the treatment and follow-up phases for their health and response to therapy.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effects of TQF3250 capsules in adults with type 2 diabetes who are also overweight or obese. This Phase 1b, multi-center, randomized, double-blind, placebo-controlled study plans to enroll 72 participants divided into six dose groups ranging from 4 mg to 40 mg, with a dose-escalation design. Participants will take TQF3250 capsules or a matching placebo orally once daily under fasting conditions for 12 weeks. Each dose group includes 12 subjects, randomized in a 102 ratio to receive either the study drug or placebo. The dosing will follow a titration regimen, gradually increasing to the target dose. During the study, participants will have regular assessments including safety evaluations such as monitoring adverse events and clinical examinations. Pharmacokinetic measurements will be taken at multiple time points before and after dosing, while efficacy will be evaluated through tests like glycated hemoglobin HbA1c, oral glucose tolerance test, body weight, waist circumference, body mass index, fasting plasma glucose, C-peptide, and insulin levels. The total participation lasts about 14 weeks, including follow-up for safety and tolerability.
Actively Recruiting
Researchers are evaluating the efficacy and safety of LBL-024 combination therapy for patients with advanced non-small cell lung cancer NSCLC, a type of advanced solid tumor. This open-label, multicenter Phase II study aims to understand how well LBL-024 works when given alongside other cancer drugs. The study includes four groups of participants to assess different drug combinations and treatment approaches. Participants receive LBL-024 combined with drugs such as docetaxel, bevacizumab, pemetrexed, carboplatin, or paclitaxel through intravenous infusion. Each group starts with a 21-day safety observation period to monitor tolerability, followed by randomized assignment to specific treatment arms if safety is confirmed. Some groups continue with maintenance therapy using LBL-024 or other drugs after initial combination treatment. During the trial, participants undergo regular assessments including physical exams, laboratory tests, and imaging to monitor tumor response and safety. Researchers measure outcomes like objective response rate, disease control rate, and duration of response. Monitoring continues through a follow-up period after treatment ends to evaluate lasting effects and drug safety. The study plans to enroll up to 250 participants aged 18 to 75 years.
1-10 of 210
1